Skip to main content
. 2020 Jun 24;40(6):BSR20201175. doi: 10.1042/BSR20201175

Figure 3. CCL3 mediates osteoclastogenesis of BMMs in CRC microenvironment.

Figure 3

(A) Trap staining showing the osteoclastogenic capacity of BMMs treated by MC-38 CM plus RANKL with/without CCL3 neutralizing antibody. (B) Quantification of nuclei number per osteoclast in each group in (A). (C) Relative Trap activity assay revealing Trap activity in BMMs during osteoclastogenesis in each group in (A). (D) Immunofluorescence analysis showing the multinuclear giant cell number in BMMs treated with RANKL (Ctrl), MC-38 CM plus RANKL (CM) or MC-38 CM, RANKL, and CCL3 neutralizing antibody (CM+CCL3 nAb) (scale bar = 50 μm). (E) Quantification of multinuclear giant cells in each group in (D). Abbreviations: nAb, neutralizing antibody; CM, conditional medium; Ctrl, control; No., number. *P<0.05, **P<0.01, ***P<0.001.